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Elimination of HIV and syphilis mother-to-child transmission (MTCT) has received much
attention but little consideration has been given to the possibility of elimination of HBV
MTCT. In sub-Saharan Africa, HBV vertical transmission continues to be reported and it
remains an important public health problem. This study aimed to assess the feasibility of
screening pregnant women for HBV using a point-of-care (POC) test and implementing
interventions to prevent HBV MTCT.
Methods
In this observational prospective cohort study, HIV-uninfected pregnant women who con-
sented to testing were screened for HBV using a rapid POC test for HBsAg. Positive results
were laboratory-confirmed and tested for HBV DNA and serological markers. Women with
viral loads 20 000 IU/ml received tenofovir (TDF) treatment and all infants received birth-
dose HBV vaccine. Two blood samples collected six months apart from HBV-exposed
infants within their first year of life were tested for HBV DNA.
Results
Of 144 women who were approached, 134 consented to participating (93% acceptance rate
of HBV POC test). Six women tested positive for HBsAg (4.5%; 95% CI 0.99%–8.01%), all
confirmed by laboratory testing. Two mothers, M1 and M4, were treated with TDF during
their third trimester of pregnancy. Six HBV-exposed infants received the HBV vaccine within
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24 hours of birth, of whom two were lost to follow-up and four (including the two born to M1
and M4) had undetectable levels of HBV DNA when tested at the two time points.
Conclusion
We found that HBV screening using POC testing fulfilled the criteria considered necessary
for implementation. It has acceptable performance, is inexpensive, reliable, and was well
accepted by the study participants. Screening pregnant women as part of the HBV MTCT
prevention strategy is therefore feasible in a South African clinical setting.
Introduction
Hepatitis B virus (HBV) infection causes substantial, and largely unappreciated, morbidity and
mortality. Globally, it is estimated that 248 million people have an active HBV infection [1]
and that every year 686 000 people die as a direct consequence of this infection [2]. This is
despite the availability of a safe and effective vaccine and potent antiviral therapy.
Acute HBV infection in the immunocompetent adult is likely to be cleared. However, peri-
natal transmission of HBV in neonates and horizontal transmission in young children carry a
high risk of chronicity, which can result in serious complications such as liver cirrhosis and
hepatocellular carcinoma. Around 90% of those infected at delivery will become chronic carri-
ers, whilst less than 5% of adults will develop chronic infections [3]. Efforts to control ongoing
infection with HBV should, therefore, be focused on preventing infection in the neonate [4].
The World Health Organization (WHO) recommends administration of the first dose of
the hepatitis B (HB) vaccine within 24 hours of delivery [5]. There are perceived difficulties
with the implementation of this recommendation [6]. Many pregnant women do not have
access to the vaccine because there are no national guidelines or policies on the use of the
birth-dose vaccine, they do not deliver in healthcare facilities, and with the rollout of the hexa-
valent vaccine (DTaP-IPV-HB-Hib) in South Africa, vaccination against HBV at birth would
need to be administered as a single separate vaccine, adding cost to the schedule.
Furthermore, infants of mothers who are HBeAg positive or who have high HB viral loads
are at higher risk of perinatal infection than women who have lower viral loads. A meta-analy-
sis investigating the risk of perinatal transmission of HBV in Sub-Saharan Africa showed that
in HBeAg-positive women, the pooled risk of transmission was 38.3% (95% CI: 7.0–74.4%)
compared to only 4.8% (95% CI: 0.1–13.3%) in HBeAg-negative women [7]. According to
international guidelines, such as the American Association for the Study of Liver Diseases
(AASLD) and the European Association for the Study of the Liver (EASL) guidelines, HBV-
exposed infants should receive both hepatitis B immunoglobulin (HBIG) and HBV birth-dose
vaccine to further reduce the risk of transmission [8,9]. However, HBIG is not available in
many resource-poor settings due to its high cost and the logistics of storage and administra-
tion. Antiviral therapy during pregnancy reduces the risk of HIV transmission. Nucleoside or
nucleotide analogues, for example, lamivudine or tenofovir (TDF), when administered around
28 to 32 weeks of gestation reduce maternal HB viral load during pregnancy and therefore the
risk of mother-to-child transmission (MTCT) [10,11]. Antiviral treatment of HBV-infected
mothers with high viral loads should be considered in order to reduce the risk of perinatal
transmission.
Sub-Saharan Africa (SSA), after Asia, carries the highest burden of HBV infection [1]. Ante-
natal screening for HBV infection is currently not performed in the public sector in South
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Africa, but it is the key step in identifying those women most at risk of transmitting infection
and allowing the implementation of preventive strategies.
This study was carried out to assess the feasibility of (i) screening pregnant women for hep-
atitis B surface antigen (HBsAg) using a point of care (POC) test, (ii) offering antiviral treat-
ment to those women with viral loads greater than 20 000 IU/ml since HBIG was not easily
available, and (iii) administering HBV birth-dose vaccine to infants of HBV-infected mothers




This observational prospective cohort study was approved by the Health Research Ethics Com-
mittee of Stellenbosch University, Cape Town, South Africa (N13/10/132) and conformed to
the 1975 Declaration of Helsinki. From June to November 2014, HIV-uninfected pregnant
women already enrolled in an ongoing unrelated study at Tygerberg Hospital, a tertiary care
hospital in Cape Town, South Africa, were approached for participation. The study nurse pro-
vided an information session on HBV, the study aims, and offered HBV POC testing to poten-
tial study participants.
Maternal HBV testing: Screening, confirmation, and additional markers
The women provided written informed consent before their participation in this study and
were counselled and screened for HBsAg by a trained and experienced research nurse. A finger
prick blood sample was taken from each participant and tested using the Determine™ HBsAg
point-of-care test (Alere Inc., MA, USA). This assay was chosen because of its acceptable per-
formance [12]. Additional venous blood samples were collected from those with positive
screening test results for confirmatory HBsAg testing and subsequent testing for additional
HBV markers (anti-HBc [total and IgM], HBeAg, and anti-HBe) on the ARCHITECT
i2000SR automated system (Abbott Laboratories, IL, USA). In addition, these participants had
their HBV DNA levels quantified using the automated COBAS1 AmpliPrep/COBAS1 Taq-
Man1 HBV Test, v2.0 (Roche Molecular Systems, NJ, USA). The limit of quantification of this
viral load assay using serum samples was 20 IU/ml. If a patient had a detectable but unquantifi-
able viral load (i.e., below 20 IU/ml), their result was reported as< 20 IU/ml. However, if the
patient had undetectable viral loads, their result was reported as lower than the detectable limit
(LDL). In all cases, the viral load results were interpreted in conjunction with the patient’s clin-
ical status, which included the patient’s liver function tests, clinical examination and serologi-
cal results and whether there was any clinical evidence of liver cirrhosis (clinical signs of
chronic liver disease or liver dysfunction observed either on ultrasound or abnormal liver
function tests). Genotyping was also performed on DNA extracted from the maternal serum
samples using an in-house PCR assay targeting the polymerase/surface region of the viral
genome [13].
Interventions to prevent MTCT of HBV: Treatment and vaccination
International guidelines, such as the AASLD guidelines, do not recommend treating women
with HB viral loads lower than 200 000 IU/ml as their infants will be receiving both HBIG and
HBV birth-dose vaccine. However, in the present study, since HBIG was not available for use
owing to its high cost, treatment was discussed and offered to participating pregnant women
with HB viral loads greater than 20 000 IU/ml. Those who qualified for treatment under these
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criteria were reviewed at the Hepatology Clinic and offered a 300 mg TDF tablet daily, starting
after 28 weeks gestation until one month after delivery. The women were monitored for
hepatic flares for one month post-treatment. The risks and benefits of therapy were clearly
explained. All HBV-exposed infants received a birth dose of the standard monovalent, yeast-
derived HBV vaccine (Heberbiovac HB: 10 μg in 0.5 ml). They were subsequently vaccinated
with the hexavalent vaccine (Hexaxim1 Sanofi Pasteur: 10 μg of HBsAg in 0.5 ml) at 6 and 10
weeks [5].
Infant HBV testing: Screening and follow-up
A heel prick whole blood sample was collected from each HBV-exposed infant as soon as
possible after birth and spotted onto a Guthrie card. The dried blood spots (DBS) thus
obtained were eluted overnight in COBAS1 AmpliPrep/COBAS1 TaqMan1 Specimen Pre-
Extraction Reagent (SPEX) and tested for HBV DNA using the automated COBAS1 Ampli-
Prep/COBAS1 TaqMan1 HBV Test, v2.0 (Roche Molecular Systems, NJ, USA). The limit of
quantification of this viral load assay using DBS was 1000 IU/ml. If a patient had a detectable
but unquantifiable viral load (i.e., below 1000 IU/ml), their result was reported as< 1000 IU/
ml. If a patient had an undetectable viral load, their result was reported as lower than the detec-
tion limit (LDL). Just as for the adult cases, the viral load results were interpreted in conjunc-
tion with the patient’s clinical status and serological results.
A serum sample was collected from HBV-exposed infants seven months after the initial
HBV test to determine their HBsAg status and whether any previously positive infant had a
persistent, and therefore chronic, HBV infection. This sample was tested for serological mark-
ers of HBV infection (HBsAg and anti-HBc IgM) and immunity (anti-HBs) and for HBV
DNA and HBV genotype, using the same assays described above for the maternal samples.
Results
Study population
The study nurse approached 144 HIV-uninfected pregnant women for this study. Only ten
women declined to participate in this study. The reasons provided for not participating were
as follows: reticence to be tested for a sexually transmitted disease and inconvenience of com-
ing back to the hospital for follow-up testing for study purposes. A total of 134 women were
thus enrolled, giving the HBV POC test a 93% acceptance rate. Their mean age was 26.1
(range: 18–40) years and all were in their second (62/134) or third trimester (72/134) of
pregnancy.
Maternal HBV testing
Of the 134 women, six had reactive HBsAg screening test results (4.5%; 95% CI 0.99%–8.01%).
All were confirmed by laboratory-based testing. There were no indeterminate results. Their
mean age was 27 (range: 21–34 years). The results from serological and molecular tests per-
formed on the women (coded M1 to M6) are presented in Table 1. Mothers M1, M2, M4, and
M6 were infected with HBV subgenotype D3 and mother M5 with HBV subgenotype A1. The
HB viral load of mother M3 was too low for sequencing.
Interventions to prevent MTCT of HBV
Mothers M2, M3, M5, and M6 had low HB viral loads and therefore were considered to be at
low risk of transmitting HBV to their infants perinatally [14]. Mothers M1 and M4 had higher
HB viral loads and were therefore offered antiviral treatment with TDF at 36 and 28 weeks of
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pregnancy, respectively. One month after giving birth, mother M1’s treatment was discontin-
ued and she was monitored for any hepatic flares for one additional month. She remained well
after stopping TDF. When she was tested one month after giving birth, her viral load was < 20
IU/ml. Mother M4 was not tested post-delivery as she declined to attend her hospital appoint-
ment. However, she was contacted telephonically and indicated that she remained well.
All six infants (coded C1 to C6 and born to mothers M1 to M6 respectively) received the
first dose of the HBV vaccine at birth and subsequently the second and third doses at ages 6
and 10 weeks, respectively. Although infants C5 and C6 were lost to follow-up, mothers M5
and M6 were contacted telephonically and verbally confirmed taking C5 and C6 for their
6-week and 10-week vaccinations.
Infant HBV testing
DBS were collected from four of six HBV-exposed infants (C1 to C4) at a mean age of 97 days
(range: 34–151 days). Two infants, C5 and C6 born to mothers M5 and M6, were lost to fol-
low-up. The four tested infants, C1 to C4, were all male. All four DBS samples had undetect-
able levels of DNA. Follow-up serum samples were collected from those four infants seven
months after the first sample at a mean age of 328 (274–381) days. All four infants had unde-
tectable levels of HBV DNA and protective levels of anti-HBs (Table 2). They also tested nega-
tive for anti-HBc IgM.
Discussion
Feasibility of implementation of HBV POC testing
This study describes the implementation of HBsAg screening in an antenatal clinic in the
Western Cape, South Africa. Screening tests typically are required to fulfil the Wilson-Jungner
criteria [15] to be considered suitable for implementation. Firstly, the disease being identified
(in this case HBV infection) needs to be a major health problem that can be detected in the
early stages using the screening test and confirmed using diagnostic tests that should be avail-
able and accessible to the tested population. Furthermore, the latest WHO guidelines recom-
mend routinely offering HBsAg testing to pregnant women in settings with a2% HBsAg
seroprevalence in the general population [16]. HBV is a serious unrecognised and under-diag-
nosed public health issue in South Africa, with a reported prevalence as high as 23% in HIV-
infected individuals from the Limpopo province [17]. In the current study, the prevalence of
Table 1. Serological and molecular maternal results.
Mother HBsAg* HBeAg Anti-HBe Anti-HBc IgM Anti-HBc (total) HBV DNA (IU/ml) HBV genotype
M1 + − + − + 23 000 D3
M2 + − + − + 5120 D3
M3 + − + − + 91 ND#
M4 + + − − + 767 000 D3
M5 + − − − + 336 A1
M6 + − + − + 161 D3
IU/ml: International Units per millilitre; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B envelope antigen; Anti-HBe: antibody to hepatitis B envelope
antigen; Anti-HBc: antibody to hepatitis B core antigen; IgM: Immunoglobulin M; HBV: hepatitis B virus; M: HBV-infected mother; −: Negative; +: Positive;
ND: Not done.
* HBsAg status was determined by point-of-care testing (Determine™, Alere Inc., USA) and confirmed by ELISA (ARCHITECT i2000SR, Abbott, USA).
# Sequencing not possible due to low viral load.
https://doi.org/10.1371/journal.pone.0181267.t001
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HBsAg in HIV-uninfected pregnant women was 4.5%, which is slightly higher than the preva-
lence of 2.9% which was reported in a previous study on HIV-uninfected pregnant women
from the Western Cape Province, South Africa [18]. Although the seroprevalence of HBsAg in
the general South African population is currently unknown, it is clear that the HBsAg preva-
lence observed in the current and previous studies are worrying and justify the introduction of
HBV POC testing, particularly for pregnant women. HBV POC testing in pregnant women
can identify those who are actively infected and at risk of transmitting HBV to their children.
Further diagnostic testing may be performed to better quantify the risk of transmission.
Secondly, treatment for the disease should be available and accessible to the tested popula-
tion. Of the six women diagnosed with active HBV infection in the present study, two (M1 &
M4) had high viral loads and were therefore at high risk of transmitting HBV to their infants.
It was interesting to note that four of five sequenced mothers were infected with subgenotype
D3 even though the most prevalent genotype in South Africa is A1. They were able to access
treatment through the public health care system. Furthermore, all HBV-exposed children in
this study received HBV birth-dose vaccine. The combined effect of these interventions was
successful in preventing HBV MTCT including in the two high-risk cases. All four infants
were negative for HBV markers of infection, including HBsAg and anti-HBc IgM, when tested
at two different time points, six months apart.
Thirdly, the test needs to be acceptable to the population. The present study found that
HBV POC testing was acceptable to most pregnant women with only a few objecting to being
tested (10/144). We believe that if knowledge of the disease and testing were to become more
widespread, acceptability would increase further as has been demonstrated previously with
HIV counselling and rapid antibody testing [19].
Finally, the test itself needs to be sensitive, specific, easy to use, non-invasive, quick, and
cost-effective. This study found that all positive rapid test results were confirmed to be true-
positives in the laboratory, giving the test 100% specificity for the present study. We cannot
comment on the sensitivity of the test in this study since the negative results were not con-
firmed; however, previous studies have reported the pooled sensitivity of the test to be 97.6%
(95% Credible Interval: 96.3%–98.6%) and the analytical sensitivity of the Determine™ HBsAg
test to be between 1 and 2 IU/ml [12,20]. We also cannot fully exclude the possibility that false
negatives may have occurred as reported elsewhere [21]; however, this is unlikely, since the
prevalence of active HBV infection observed in this study was 4.5% (95% CI: 0.99%–8.01%),
which is in line with our previous data for a Western Cape maternal population [18]. Although
Table 2. Serological and molecular infant results.
1st sample (DBS) 2nd sample (serum)
Child HBV DNA HBsAg Anti-HBc (IgM) HBsAg Anti-HBs* HBV DNA
C1 LDL# − − − 525 LDL#
C2 LDL# − − − 629 LDL#
C3 LDL# − − − 350 LDL#
C4 LDL# − − − 360 LDL#
The DBS were collected at a mean age of 97 days (range: 34–151 days) and the serum at a mean age of 328 (274–381) days. C1 was born to mother M1,
C2 to mother M2, C3 to mother M3, and C4 to mother M4.
DBS: Dried blood spot; HBsAg: hepatitis B surface antigen; Anti-HBc: antibody to hepatitis B core antigen; IgM: Immunoglobulin M; Anti-HBs: antibody to
hepatitis B surface antigen; HBV: hepatitis B virus; C: HBV-exposed child; −: Negative;
*: Anti-HBs levels measured in mIU/ml.
#: LDL—Lower than detectable limit. The viral load was below the detection limit of the assay.
https://doi.org/10.1371/journal.pone.0181267.t002
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no economic analyses were performed within the present study, a recent community-based
study from The Gambia, where the HBsAg prevalence is 8.8%, found that a screen-and-treat
intervention would produce an incremental cost-effectiveness ratio (ICER) of $540 per disabil-
ity-adjusted life year averted, which was considered to be highly cost-effective as it was in line
with the WHO’s willingness-to-pay level of once the country’s gross domestic product-per-
capita ($487). When the HBsAg prevalence was reduced to 5%, the ICER increased slightly to
$633 but was still considered to be cost-effective [22], suggesting that a similar intervention
could also be potentially cost-effective in South Africa.
Feasibility of implementation of HBV POC testing—The South African
socio-political context
Several international guidelines have addressed the management of pregnant women with
chronic hepatitis B. In Asia, which has the highest burden of HBV worldwide, the Asian Pacific
Association for the Study of the Liver (APASL) recommends screening pregnant women dur-
ing their first trimester so that unprotected mothers can be vaccinated against HBV and HBV-
infected mothers can be treated as early as possible if necessary [23]. The AASLD guidelines
also strongly recommend treating women with HB viral loads higher than 200 000 IU/ml in
the third trimester of pregnancy until delivery and providing both HBIG and HBV birth-dose
vaccine to the infant [8]. However, in the present study, HBIG was not accessible and therefore
could not be administered to the HBV-exposed infants; an HB viral load of 20 000 IU/ml was
therefore selected as a cut-off to offer treatment. Both guidelines recommend the use of TDF
as the treatment of choice in pregnant women and recent studies have shown that the use of
TDF is safe during pregnancy and breastfeeding and does not affect early childhood develop-
ment [10,24,25].
The failure in South Africa to screen pregnant women for HBsAg and to vaccinate infants
at delivery perpetuates the cycle of infection in high-risk communities. Routine HBV screen-
ing can and should be implemented using existing prenatal POC testing infrastructures, along-
side HIV and syphilis POC tests, that are already offered to pregnant women in South Africa
following the ‘opt-out provider-initiated testing and counselling’ (opt-out PITC) model. In the
opt-out PITC model, rapid HBV testing would be offered to all pregnant women presenting at
a healthcare facility. The pregnant women could then decide whether to get tested or not. This
model has been shown to increase the uptake of HIV testing and this would be especially bene-
ficial for HBV testing as it is currently a largely unknown disease to the general South African
public.
For those women who require treatment, TDF is accessible in South Africa, either as the sin-
gle drug Viread1 or in combination form as Truvada1. Although in the Western Cape Prov-
ince Viread1 has been prescribed to treat HBV mono-infection through the public and private
health care systems, access to the treatment has been notoriously difficult as mono-infected
patients in the public health care system could previously only access medication at a tertiary
hospital. However, since mid-2016, this access has been extended to local day hospitals. HBV/
HIV co-infected patients would preferentially receive Truvada1 as it is generally prescribed as
first-line therapy in HIV-infected individuals. Unlike Viread1, Truvada1 is available free of
charge at primary health care clinics, making it easier for HIV/HBV co-infected patients to
access treatment than HBV mono-infected patients. In 2016, Truvada1 was also approved for
use in HIV prevention in South Africa and in the context of pre-exposure prophylaxis against
HIV, appears that it can also be safely administered to HBV mono-infected individuals [26].
The WHO and a number of major international liver health organisations (e.g. EASL,
AASLD, APASL) strongly recommend that all children born to HBV-infected mothers should
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receive a birth dose of the HBV vaccine to reduce the risk of vertical transmission [8,9,23,27].
Subsequent doses of the HBV vaccine can then be administered as part of the hexavalent (DTa-
P-IPV-HB-Hib) vaccines that are routinely administered to infants as part of the EPI at 6, 10,
and 14 weeks [27]. While there are some structural barriers to the implementation of the HBV
birth-dose vaccine, they are not insurmountable [6]. In SSA, many pregnant women do not
have access to the vaccine because they do not deliver in healthcare facilities and there is a cold
chain requirement for vaccines. However, the HBV vaccine has been shown to be stable out-
side of the cold chain, making it possible for vaccination to be administered outside of a health
care setting [28].
In South Africa, the monovalent HBV vaccine will no longer be supplied to the Expanded
Programme on Immunisation (EPI), as the HBV vaccine is incorporated in the newly intro-
duced hexavalent DTaP-IPV-HB-Hib vaccine which is administered at age 6, 10 and 14 weeks.
Therefore, HBV-exposed infants urgently needing a birth-dose vaccine will need to receive
either an HBV vaccine, which will have to be purchased privately or a half-dose of the adult
monovalent vaccine (Heberbiovac HB: 20 μg in 1 ml). This again is not part of the standard
EPI repertoire of vaccines and thus not affordable for many families. This development poses
an unnecessary additional hurdle to transpose the WHO recommendation for general intro-
duction of an HBV birth-dose vaccine within the South African EPI.
The lack of political will in South Africa has been detrimental to the implementation of
HBV health policies. The South African Department of Health needs to intervene and put into
place national guidelines that recommend and support introduction of the birth-dose vaccine,
screening of pregnant women, and treatment for those who qualify for it. Only then will we be
able to begin to control the ongoing cycle of HBV infection in communities in South Africa.
Limitations
The major limitation of this study was that it was conducted at a tertiary hospital, following
recruitment in primary care by a dedicated study team. The feasibility of implementation in a
primary care antenatal clinic setting should be addressed in future studies. Furthermore, the
sample size was small as this was designed to be a pilot study. A larger study of pregnant
women in a primary health care setting is currently underway.
Conclusions
HBV is an important public health problem that requires more attention. We have shown that
screening pregnant women for HBV is feasible in a South African clinical setting. Screening
for HBV infection fulfils the Wilson-Jungner criteria. The POC test is reliable, inexpensive,
and was readily accepted by the participants of this study. This study also provided some evi-
dence that screening pregnant women, providing antivirals to treat those with high HB viral
loads, and providing HBV birth-dose vaccine to HBV-exposed infants can be implemented in
South Africa. This data supports the call to South African politicians and policymakers to
establish clear guidance on the prevention of HBV MTCT. It is only this which will reduce the
perpetual cycle of infection in African communities and enable us to reduce, indeed eliminate
this eminently preventable infection.
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